FREEZE-DRIED PLASMA (FDP): FDA APPROVES EZPLAZ™, THE FIRST FREEZE-DRIED PLASMA PRODUCT FOR CLINICAL USE IN THE UNITED STATES. IMPLICATIONS FOR MASSIVE HEMORRHAGE MANAGEMENT, TRAUMA, AND TACTICAL MEDICINE (2026 UPDATE)
By DrRamonReyesMD
EMS Solutions International
https://emssolutionsint.blogspot.com/
Abstract
Massive hemorrhage remains one of the leading preventable causes of death among severely injured patients in both civilian and military settings. Early correction of trauma-induced coagulopathy through balanced transfusion strategies is a cornerstone of modern damage control resuscitation.
On July 29, 2026, the U.S. Food and Drug Administration (FDA) approved EZPLAZ™ Freeze-Dried Plasma, making it the first freeze-dried plasma product authorized for clinical use in the United States. This milestone overcomes one of the major limitations of conventional Fresh Frozen Plasma (FFP)—the need for frozen storage and thawing before administration—allowing room-temperature storage and rapid reconstitution during time-critical emergencies.
Introduction
Since the conflicts in Iraq and Afghanistan, freeze-dried plasma has attracted considerable interest because of its potential applications in:
- Tactical Combat Casualty Care (TCCC)
- Tactical Emergency Casualty Care (TECC)
- Aeromedical evacuation
- Military medicine
- Prehospital emergency care
- Rural healthcare
- Disaster medicine
- Mass casualty incidents
For many years, several European countries have incorporated freeze-dried plasma into military and civilian trauma systems, while the United States relied primarily on special authorization programs and military protocols. FDA approval represents a historic milestone in transfusion medicine.
What Is Freeze-Dried Plasma?
Freeze-Dried Plasma (FDP) is a human plasma product derived from a single unit of Fresh Frozen Plasma (FFP) that undergoes a lyophilization process.
Lyophilization removes water through freezing and vacuum sublimation while preserving:
- Coagulation factors
- Albumin
- Immunoglobulins
- Plasma proteins
- Coagulation regulatory proteins
After reconstitution with sterile water, the product regains functional characteristics comparable to conventional plasma.
What Is EZPLAZ™?
EZPLAZ™ is a biologic product developed by Vascular Solutions, a Teleflex company, and approved by the FDA for plasma transfusion in adult patients when other plasma products are unavailable.
Key Features
- Human freeze-dried plasma
- Derived from a single unit of Fresh Frozen Plasma
- Contains clinically relevant coagulation factors
- Room-temperature storage
- Rapid reconstitution
- Durable plastic bag presentation suitable for austere environments
Technical Characteristics
According to the FDA-approved product information:
- Group AB plasma
- Group A plasma with low-titer anti-B antibodies
- Approximately 270 mL of plasma after reconstitution
- Reconstituted with 250 mL of Sterile Water for Injection
- Intravenous (IV) or intraosseous (IO) administration
- Storage at room temperature for up to 12 months while maintaining clinically meaningful coagulation factor activity
Approved Indications
The FDA authorizes its use in adults when plasma is required and conventional plasma products are not immediately available, including:
1. Multiple Coagulation Factor Deficiency
Examples include:
- Severe liver disease
- Disseminated Intravascular Coagulation (DIC)
- Perioperative bleeding requiring coagulation factor replacement
2. Massive Transfusion
Patients with severe hemorrhage who develop clinically significant coagulopathy.
3. Urgent Warfarin Reversal
Patients receiving warfarin who present with active bleeding or require emergency surgery.
Why Is This Approval So Important?
Traditional Fresh Frozen Plasma has several logistical limitations:
- Continuous frozen storage
- Cold-chain transportation
- Thawing time of approximately 20–40 minutes
- Potential delays in coagulation factor replacement
Freeze-dried plasma effectively eliminates most of these barriers.
Operational Advantages
Major advantages include:
- Immediate availability
- No requirement for freezers
- Simplified transportation
- Reduced risk of bag rupture due to durable plastic packaging
- Ideal for ambulances, helicopters, and rural hospitals
- Particularly valuable in combat operations and disaster response
Importance in Trauma Care
Trauma-induced coagulopathy develops early following severe hemorrhage.
Delayed plasma administration contributes to:
- Progression of hemorrhagic shock
- Metabolic acidosis
- Hypothermia
- Consumption of coagulation factors
- Increased mortality
Having plasma that can be reconstituted within minutes allows earlier initiation of hemostatic resuscitation.
Applications in Tactical Medicine
Freeze-Dried Plasma has particular relevance in:
- Tactical Combat Casualty Care (TCCC)
- Tactical Emergency Casualty Care (TECC)
- Aeromedical evacuation
- Military medicine
- Special operations forces
- Tactical law enforcement medicine
- Remote rescue operations
- Offshore medicine
In these environments, transport times to a blood bank may extend for several hours.
Intraosseous Administration
A major advantage of EZPLAZ™ is its compatibility with intraosseous (IO) administration, enabling early coagulation factor replacement even when intravenous access is difficult or impossible.
ABO Compatibility
EZPLAZ™ is available as:
- Group AB plasma
- Group A plasma with low-titer anti-B antibodies
Low-titer Group A plasma has become an accepted alternative to universal AB plasma in many massive transfusion protocols because of its greater availability.
Safety
Like all blood products, Freeze-Dried Plasma carries potential risks, including:
- Transfusion reactions
- Transfusion-Associated Circulatory Overload (TACO)
- Transfusion-Related Acute Lung Injury (TRALI)
- Allergic reactions
- Transmission of infectious agents (substantially minimized through current donor screening and manufacturing processes)
Impact on Emergency Medical Services
FDA approval of Freeze-Dried Plasma has the potential to significantly influence:
- Emergency Medical Services (EMS)
- Air medical transport programs
- Trauma centers
- Tactical medical teams
- Field hospitals
- Military medical systems
Its immediate availability may shorten the time required to correct coagulopathy and improve care in environments where conventional Fresh Frozen Plasma is logistically impractical.
Future Perspectives
The introduction of EZPLAZ™ is expected to stimulate:
- Additional comparative studies with Fresh Frozen Plasma
- Expansion of prehospital plasma administration
- Broader integration into massive transfusion protocols
- Increased plasma availability in remote, military, and disaster settings
Although current FDA approval is limited to situations where other plasma products are unavailable, many experts believe this marks the beginning of a new era in transfusion medicine.
Conclusions
The FDA approval of EZPLAZ™, the first freeze-dried plasma product authorized for clinical use in the United States, represents one of the most significant advances in transfusion medicine in recent years.
Its ability to be stored at room temperature, rapidly reconstituted, and administered through either intravenous or intraosseous routes makes it an invaluable tool for the management of massive hemorrhage and trauma-induced coagulopathy, particularly in prehospital, military, rural, and disaster environments.
If ongoing clinical experience and post-marketing data confirm current expectations, freeze-dried plasma has the potential to fundamentally transform hemostatic resuscitation in patients with life-threatening hemorrhage.
References
-
U.S. Food and Drug Administration (FDA). Emergency Use Authorization: Freeze-Dried Plasma. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
-
Reuters. US FDA Approves First Freeze-Dried Plasma Product. July 29, 2026.
-
Joint Trauma System. Clinical Practice Guideline: Damage Control Resuscitation.
-
Association for the Advancement of Blood & Biotherapies (AABB). Standards for Blood Banks and Transfusion Services.
-
Rossaint R, et al. European Guideline on Management of Major Bleeding and Coagulopathy Following Trauma. European Journal of Trauma and Emergency Surgery.
No hay comentarios:
Publicar un comentario